NP49425 Generic and Biosimilar Transition Medicines

{
  "buyer": {
    "id": "org-29",
    "name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)"
  },
  "date": "2025-08-21T00:00:00Z",
  "description": "The estimated values referred to in Section II.1.5 and within all Lots cover the initial contract duration and extension period of the Framework Agreement in respect of each Lot.\r\n The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 60353 . For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343\r\n A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363\r\n Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/\r\n A summary of the expected community benefits has been provided as follows:\r\n It is a mandatory requirement that potential Framework Participants agree to support the concept, provision, and ongoing development of community benefits provision in relation to this Framework Agreement.\r\n Framework Participants are required to agree to this mandatory requirement. They are also requested to provide a summary of the community benefits that have recently been delivered within Scotland, if at all, and what impact and outcomes these have achieved.\r\n Framework Participants are required to summarise any proposed community benefits that will be developed and delivered as part of this Framework Agreement if successful or, alternatively, potential Framework Participants confirm that they will engage with the NHS Scotland\u00e2\u0080\u0099s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits.\r\n For further information please visit NHSS Community Benefit Gateway (https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/).\r\n (SC Ref:807501)",
  "id": "rls-23-AUG537425",
  "initiationType": "tender",
  "language": "EN",
  "links": [
    {
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000807501",
      "rel": "canonical"
    }
  ],
  "ocid": "ocds-r6ebe6-0000807501",
  "parties": [
    {
      "address": {
        "locality": "Edinburgh",
        "postalCode": "EH12 9EB",
        "region": "UKM",
        "streetAddress": "1 South Gyle Crescent"
      },
      "contactPoint": {
        "email": "nss.pcfparamed@nhs.scot",
        "telephone": "+44 1312756000",
        "url": "http://www.publictendersscotland.publiccontractsscotland.gov.uk"
      },
      "details": {
        "classifications": [
          {
            "id": "Body governed by public law",
            "scheme": "TED_CA_TYPE"
          },
          {
            "description": "Health",
            "id": "07",
            "scheme": "COFOG"
          }
        ],
        "url": "http://www.nss.nhs.scot/browse/procurement-and-logistics"
      },
      "id": "org-29",
      "identifier": {
        "legalName": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)"
      },
      "name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)",
      "roles": [
        "buyer",
        "centralPurchasingBody"
      ]
    },
    {
      "address": {
        "locality": "Edinburgh",
        "postalCode": "EH1 1LB",
        "streetAddress": "27 Chambers Street"
      },
      "contactPoint": {
        "email": "edinburgh@scotcourts.gov.uk",
        "telephone": "+44 1312252525",
        "url": "https://scotcourts.gov.uk/the-courts/sheriff-court/about-sheriff-courts"
      },
      "id": "org-38",
      "identifier": {
        "legalName": "Sheriff Court House"
      },
      "name": "Sheriff Court House",
      "roles": [
        "reviewBody"
      ]
    }
  ],
  "relatedProcesses": [
    {
      "id": "1",
      "identifier": "2025/S 000-046278",
      "relationship": [
        "planning"
      ],
      "scheme": "EU-OJ"
    }
  ],
  "tag": [
    "tender"
  ],
  "tender": {
    "awardPeriod": {
      "startDate": "2025-09-22T12:00:00Z"
    },
    "bidOpening": {
      "date": "2025-09-22T12:00:00Z"
    },
    "classification": {
      "id": "33600000",
      "scheme": "CPV"
    },
    "contractTerms": {
      "electronicInvoicingPolicy": "allowed",
      "hasElectronicOrdering": true,
      "hasElectronicPayment": true
    },
    "coveredBy": [
      "GPA"
    ],
    "description": "Supply of generic and biosimilar transition medicines to NHS Scotland.",
    "documents": [
      {
        "description": "Supply of generic and biosimilar transition medicines to NHS Scotland.",
        "documentType": "contractNotice",
        "format": "text/html",
        "id": "AUG537425",
        "title": "NP49425 Generic and Biosimilar Transition Medicines",
        "url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG537425"
      }
    ],
    "hasRecurrence": false,
    "id": "ocds-r6ebe6-0000807501",
    "items": [
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "1",
        "relatedLot": "1"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "2",
        "relatedLot": "2"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "3",
        "relatedLot": "3"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "4",
        "relatedLot": "4"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "5",
        "relatedLot": "5"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "6",
        "relatedLot": "6"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "7",
        "relatedLot": "7"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "8",
        "relatedLot": "8"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "9",
        "relatedLot": "9"
      },
      {
        "additionalClassifications": [
          {
            "id": "33600000",
            "scheme": "CPV"
          }
        ],
        "deliveryAddresses": [
          {
            "region": "UKM"
          }
        ],
        "deliveryLocation": {
          "description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
        },
        "id": "10",
        "relatedLot": "10"
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "lotDetails": {
      "maximumLotsBidPerSupplier": 2147483647
    },
    "lots": [
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-02-28T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of cytokine modulators (golimumab, tocilizumab, and etanercept) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "1",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)",
        "value": {
          "amount": 99950577.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-02-28T00:00:00Z",
          "startDate": "2026-04-01T00:00:00Z"
        },
        "description": "Supply of cytokine modulators (omalizumab) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "2",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Cytokine Modulators (Omalizumab)",
        "value": {
          "amount": 15643757.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-07-31T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of gastrointestinal, endocrine, blood, and multiple sclerosis medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "3",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines",
        "value": {
          "amount": 26183523.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-07-31T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of denosumab (osteoporosis) and ferric carboxymaltose to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "4",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Denosumab (Osteoporosis) and Ferric Carboxymaltose",
        "value": {
          "amount": 27420432.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-10-31T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of apremilast to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "5",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-seven (27) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Apremilast",
        "value": {
          "amount": 1495958.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2028-05-30T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "6",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Cardiovascular and Respiratory Medicines",
        "value": {
          "amount": 457484.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2028-05-30T00:00:00Z",
          "startDate": "2026-04-01T00:00:00Z"
        },
        "description": "Supply of nintedanib to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "7",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Nintedanib",
        "value": {
          "amount": 27322496.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-01-31T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of cancer medicines (group 1) to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "8",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Cancer Medicines (Group 1)",
        "value": {
          "amount": 15175245.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2027-01-31T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of cancer medicines (group 2) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "9",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Cancer Medicines (Group 2)",
        "value": {
          "amount": 21258752.0,
          "currency": "GBP"
        }
      },
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "5",
              "name": "Supply Chain",
              "type": "quality"
            },
            {
              "description": "95",
              "type": "price"
            }
          ]
        },
        "contractPeriod": {
          "endDate": "2028-09-30T00:00:00Z",
          "startDate": "2026-02-01T00:00:00Z"
        },
        "description": "Supply of psychiatry and neurology medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.",
        "hasOptions": false,
        "hasRenewal": true,
        "id": "10",
        "renewal": {
          "description": "The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of seventeen (17) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire."
        },
        "status": "active",
        "submissionTerms": {
          "variantPolicy": "notAllowed"
        },
        "title": "Psychiatry and Neurology Medicines",
        "value": {
          "amount": 60787.0,
          "currency": "GBP"
        }
      }
    ],
    "mainProcurementCategory": "goods",
    "procurementMethod": "open",
    "procurementMethodDetails": "Open procedure",
    "reviewDetails": "The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operators was unsuccessful. The notification will incorporate a \u00e2\u0080\u0098standstill period\u00e2\u0080\u0099 of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.",
    "selectionCriteria": {
      "criteria": [
        {
          "description": "Economic operators may be excluded from this competition if they are in breach of any situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.",
          "type": "suitability"
        },
        {
          "description": "(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement.\r\n AND\r\n (b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.\r\n AND\r\n (c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (\"NPSA\") Guidelines on Packaging and Labelling on pack design.\r\n AND\r\n (d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.",
          "minimum": "(a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.\r\n AND\r\n (b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.\r\n AND\r\n (c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (\"NPSA\") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.\r\n AND\r\n (d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder\u00e2\u0080\u0099s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions.",
          "type": "technical"
        }
      ]
    },
    "status": "active",
    "submissionMethod": [
      "electronicSubmission"
    ],
    "submissionMethodDetails": "https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html",
    "submissionTerms": {
      "bidValidityPeriod": {
        "durationInDays": 90
      },
      "languages": [
        "en"
      ]
    },
    "techniques": {
      "frameworkAgreement": {
        "maximumParticipants": 50.0
      },
      "hasFrameworkAgreement": true
    },
    "tenderPeriod": {
      "endDate": "2025-09-22T12:00:00Z"
    },
    "title": "NP49425 Generic and Biosimilar Transition Medicines",
    "value": {
      "amount": 234969011.0,
      "currency": "GBP"
    }
  }
}